/
Immunology
Psoriatic Arthritis
22
Pipeline Programs↗
46
Active Trials↗
30
Companies Involved↗
Psoriatic Arthritis is an emerging landscape with 22 programs across 30 companies. The most active players are AbbVie, Bristol-Myers Squibb, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical10
Phase 37
Approved
No programs
Analysis
Modality Breakdown
67%
Small molecule
12 of 18 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 95% of 22 pipeline programs.
Analysis
Trial Status
202
clinical trials
Completed124 · 61%
Recruiting25 · 12%
Terminated14 · 7%
Active, not recruiting11 · 5%
Not yet recruiting9 · 4%
Withdrawn9 · 4%
Other10 · 5%
Clinical Trials
Trial Activity
202 trials
A Randomized, Placebo- and Active Drug-Controlled, Double-Blind, Multicenter, Parallel-Group Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
Recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 2·NCT07406035·156 enrolled
Page 1 of 14
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)